Home › Companies › SUPERNUS PHARMACEUTICALS INC. › 2024-2025

SUPERNUS PHARMACEUTICALS INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and SUPERNUS PHARMACEUTICALS INC.’s Form 8-K, filed 2025-06-17 (Item 5.07 on EDGAR). Page generated 02 October 2026.

7Reported items
329Asset managers
1,745Fund votes
2025-06-16Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore SUPERNUS PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by SUPERNUS PHARMACEUTICALS INC.

These tallies are SUPERNUS PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-17 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

SUPERNUS PHARMACEUTICALS INC. — official shareholder meeting results, meeting held 2025-06-16
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Carolee Barlow, M.D., Ph.D	46,104,993	--	--	1,426,932	2,024,865	Majority: yes
Elect Director: Jack A. Khattar	46,511,003	--	--	1,020,922	2,024,865	Majority: yes
Proposal 2: To approve, on a non-binding basis, the compensation paid to our named executive officers.	45,796,936	1,701,777	33,212	--	2,024,865	Majority: yes
Proposal 3: Ratification of the appointment of KPMG LLP as the Company's independent public accounting firm for the fiscal year ending December 31, 2025.	49,230,498	310,868	15,424	--	0	Majority: yes

Source: SUPERNUS PHARMACEUTICALS INC., Form 8-K, filed with the SEC on 2025-06-17 — read the filing on EDGAR.

How asset managers voted at the SUPERNUS PHARMACEUTICALS INC. 2024-2025 meeting

Each item below shows how the 329 asset managers that disclosed a SUPERNUS PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of SUPERNUS PHARMACEUTICALS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. to approve, on a non-binding basis, the compensation paid to our named executive officers;

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 14 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 45,796,936AGAINST: 1,701,777

SUPERNUS PHARMACEUTICALS INC.’s own tally for this item (“Proposal 2: To approve, on a non-binding basis, the compensation paid to our named executive officers.”): 45,796,936 for, 1,701,777 against, per its Form 8-K filed 2025-06-17 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 55,989,248 outstanding shares: 82% for, 3% against (85% of the company cast a for/against vote).

The 323 asset managers below cast 99% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR 96%

FOR: 96.5%AGAINST: 1.2%ABSTAIN: 0.0%SPLIT: 2.3%NOT VOTED: 0.0%

Largest asset managers voting on “to approve, on a non-binding basis, the compensation paid to our named executive officers;” at SUPERNUS PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Vote
BlackRock	7,296,928	434	For
Vanguard	7,209,210	3,167	For
State Street	2,877,129	0	For
MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST	2,506,620	0	For
American Century	2,211,733	0	For
Delaware/Macquarie	2,095,715	0	For
Loomis Sayles	1,920,006	0	For
Stephens Investment Management Group LLC	1,481,514	0	For
Charles Schwab	1,463,634	0	For
Fidelity	1,415,205	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,348,923	0	For
GW&K Investment Management, LLC	23,091	0	Split
Victory Capital	899,423	0	For
Aristotle Capital Boston, LLC	860,192	0	For
Invesco	707,531	0	For
Northern Trust	660,962	0	For
ARMISTICE CAPITAL, LLC	613,459	0	For
Renaissance	554,584	0	For
PICTET ASSET MANAGEMENT SA	549,065	0	For
ASHFORD CAPITAL MANAGEMENT INC	525,334	0	For
Goldman Sachs	520,387	0	For
RICE HALL JAMES & ASSOCIATES, LLC	410,007	0	For
Pacer Funds Trust	356,772	0	For
Columbia Threadneedle	352,773	0	For
AMG FUNDS	345,099	0	For

Showing the 25 largest of 323 asset managers. See all 323 in the interactive database.

2. To elect two (2) directors to hold office for the ensuing three years and until their successors have been duly elected and qualified: Carrolee Barlow, M.D., Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 46,104,993WITHHELD: 1,426,932

SUPERNUS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Carolee Barlow, M.D., Ph.D”): 46,104,993 for, 1,426,932 withheld, per its Form 8-K filed 2025-06-17 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 55,989,248 outstanding shares: 82% for, 3% withheld (85% of the company cast a for/withheld vote).

The 103 asset managers below cast 100% of the shares they voted on this item FOR (25,237,687 for, 0 against).

FOR 98%

FOR: 25,237,687 (98.2%)ABSTAIN: 475,033 (1.8%)

Largest asset managers voting on “To elect two (2) directors to hold office for the ensuing three years and until their successors have been dul” at SUPERNUS PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	7,053,561	3,165	For
BlackRock	5,731,758	0	For
Delaware/Macquarie	2,095,715	0	For
Fidelity	1,336,571	0	For
American Century	1,083,941	0	For
State Street	907,109	0	For
Charles Schwab	704,825	0	For
Loomis Sayles	643,304	0	For
Pacer Funds Trust	356,772	0	For
Columbia Threadneedle	352,773	0	For
AMG FUNDS	345,099	0	For
Victory Capital	330,614	0	For
Goldman Sachs	319,726	0	For
Bridge Builder Trust	316,762	0	For
Invesco	0	261,854	Abstain
Brighthouse	193,532	13,189	For
MoA Funds Corp	205,507	0	For
Tributary Funds, Inc.	195,908	0	For
John Hancock	194,000	0	For
World Funds Trust	190,998	0	For
THIRD AVENUE TRUST	189,118	0	For
Lincoln Financial	183,364	0	For
Empower	155,625	0	For
Equitable	80,780	50,200	For
TIAA	0	127,610	Abstain

Showing the 25 largest of 103 asset managers. See all 103 in the interactive database.

3. To elect two (2) directors to hold office for the ensuing three years and until their successors have been duly elected and qualified: Jack A. Khattar

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 46,511,003WITHHELD: 1,020,922

SUPERNUS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Jack A. Khattar”): 46,511,003 for, 1,020,922 withheld, per its Form 8-K filed 2025-06-17 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 55,989,248 outstanding shares: 83% for, 2% withheld (85% of the company cast a for/withheld vote).

The 103 asset managers below cast 100% of the shares they voted on this item FOR (25,594,865 for, 0 against).

FOR 99.5%

FOR: 25,594,865 (99.5%)ABSTAIN: 117,757 (0.5%)

Largest asset managers voting on “To elect two (2) directors to hold office for the ensuing three years and until their successors have been dul” at SUPERNUS PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	7,056,724	2	For
BlackRock	5,731,758	0	For
Delaware/Macquarie	2,095,715	0	For
Fidelity	1,336,571	0	For
American Century	1,083,941	0	For
State Street	907,049	60	For
Charles Schwab	704,825	0	For
Loomis Sayles	643,304	0	For
Pacer Funds Trust	356,772	0	For
Columbia Threadneedle	352,773	0	For
AMG FUNDS	345,099	0	For
Victory Capital	330,614	0	For
Goldman Sachs	319,726	0	For
Bridge Builder Trust	297,821	18,941	For
Invesco	261,854	0	For
Brighthouse	193,532	13,189	For
MoA Funds Corp	205,507	0	For
Tributary Funds, Inc.	195,908	0	For
John Hancock	194,000	0	For
World Funds Trust	190,998	0	For
THIRD AVENUE TRUST	189,118	0	For
Lincoln Financial	183,364	0	For
Empower	155,625	0	For
Equitable	130,980	0	For
TIAA	127,610	0	For

Showing the 25 largest of 103 asset managers. See all 103 in the interactive database.

4. to ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025;

AUDIT-RELATEDMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.3% Majority: yes · of votes cast

FOR 99.3%

FOR: 49,230,498AGAINST: 310,868

SUPERNUS PHARMACEUTICALS INC.’s own tally for this item (“Proposal 3: Ratification of the appointment of KPMG LLP as the Company's independent public accounting firm for the fiscal year ending December 31, 2025.”): 49,230,498 for, 310,868 against, per its Form 8-K filed 2025-06-17 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 55,989,248 outstanding shares: 88% for, 0.6% against (88% of the company cast a for/against vote).

The 103 asset managers below cast 99.8% of the shares they voted on this item FOR (25,653,093 for, 46,340 against).

FOR 99.7%

FOR: 25,653,093 (99.8%)AGAINST: 46,340 (0.2%)ABSTAIN: 13,189 (0.1%)

Largest asset managers voting on “to ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year” at SUPERNUS PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Abstain	Vote
Vanguard	7,056,726	0	0	For
BlackRock	5,731,758	0	0	For
Delaware/Macquarie	2,095,715	0	0	For
Fidelity	1,336,571	0	0	For
American Century	1,083,941	0	0	For
State Street	907,049	60	0	For
Charles Schwab	704,825	0	0	For
Loomis Sayles	643,304	0	0	For
Pacer Funds Trust	356,772	0	0	For
Columbia Threadneedle	352,773	0	0	For
AMG FUNDS	345,099	0	0	For
Victory Capital	330,614	0	0	For
Goldman Sachs	319,726	0	0	For
Bridge Builder Trust	316,762	0	0	For
Invesco	261,854	0	0	For
Brighthouse	193,532	0	13,189	For
MoA Funds Corp	205,507	0	0	For
Tributary Funds, Inc.	195,908	0	0	For
John Hancock	194,000	0	0	For
World Funds Trust	190,998	0	0	For
THIRD AVENUE TRUST	189,118	0	0	For
Lincoln Financial	183,364	0	0	For
Empower	155,625	0	0	For
Equitable	130,980	0	0	For
TIAA	127,610	0	0	For

Showing the 25 largest of 103 asset managers. See all 103 in the interactive database.

5. To consider and vote upon a stockholder proposal, if included in our Proxy Statement for the Annual Meeting of Stockholders (the "Proxy Statement") and properly presented at the meeting.

CORPORATE GOVERNANCE

Combines 2 wordings of this item as funds reported it.

54.6% fund support · no official result

ABSTAIN 96%

The 45 asset managers below cast 54.6% of the shares they voted on this item FOR (237,570 for, 197,411 against).

FOR: 237,570 (2.4%)AGAINST: 197,411 (2.0%)ABSTAIN: 9,335,177 (95.5%)

Largest asset managers voting on “To consider and vote upon a stockholder proposal, if included in our Proxy Statement for the Annual Meeting of” at SUPERNUS PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Abstain	Vote
BlackRock	0	0	5,731,758	Abstain
Charles Schwab	0	0	704,825	Abstain
Loomis Sayles	0	0	643,304	Abstain
Pacer Funds Trust	0	0	356,772	Abstain
AMG FUNDS	0	0	345,099	Abstain
Bridge Builder Trust	0	0	316,762	Abstain
Tributary Funds, Inc.	0	0	195,908	Abstain
John Hancock	0	0	194,000	Abstain
World Funds Trust	0	0	190,998	Abstain
THIRD AVENUE TRUST	189,118	0	0	For
Jackson National	0	0	108,818	Abstain
QUANTITATIVE MASTER SERIES LLC	0	0	86,041	Abstain
BRUCE FUND INC	0	82,105	0	Against
Aristotle Funds Series Trust	0	0	76,381	Abstain
JPMorgan	0	0	72,507	Abstain
EA Series Trust	48,451	0	0	For
SEI	0	0	46,537	Abstain
Pear Tree Funds	0	43,100	0	Against
TARGET PORTFOLIO TRUST	0	0	37,200	Abstain
Russell Investments	0	35,858	0	Against
Transamerica	0	0	32,400	Abstain
Global X	0	0	30,325	Abstain
MASTER INVESTMENT PORTFOLIO	0	0	29,567	Abstain
CLEARWATER INVESTMENT TRUST	0	0	29,311	Abstain
Goldman Sachs	0	0	23,091	Abstain

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

6. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

96% Majority: yes · of votes cast

FOR 96%

FOR: 45,796,936AGAINST: 1,701,777

The 6 asset managers below cast 100% of the shares they voted on this item FOR (246,248 for, 0 against).

FOR 100%

FOR: 246,248 (100.0%)

Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at SUPERNUS PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Vote
JPMorgan	123,210	For
GuideStone	72,134	For
Empower	42,519	For
Cornerstone Investment Partners, LLC	4,274	For
CLEARWATER INVESTMENT TRUST	3,308	For
HC CAPITAL TRUST	803	For

7. TO CONSIDER AND VOTE UPON A STOCKHOLDER PROPOSAL, IF INCLUDED IN OUR PROXY STATEMENT FOR THE ANNUAL MEETING OF STOCKHOLDERS (THE PROXY STATEMENT&QUOT) AND PROPERLY PRESENTED AT THE MEETING. &QUOT

CORPORATE GOVERNANCE

0% fund support · no official result

AGAINST 100%

The 3 asset managers below cast 0% of the shares they voted on this item FOR (0 for, 12,693 against).

AGAINST: 12,693 (100.0%)

Largest asset managers voting on “TO CONSIDER AND VOTE UPON A STOCKHOLDER PROPOSAL, IF INCLUDED IN OUR PROXY STATEMENT FOR THE ANNUAL MEETING OF” at SUPERNUS PHARMACEUTICALS INC., 2024-2025
Asset manager	Against	Vote
TIMOTHY PLAN	11,285	Against
RBB Fund Trust	1,188	Against
Advisors' Inner Circle Fund III	220	Against

Largest SUPERNUS PHARMACEUTICALS INC. shareholders voting in 2024-2025

Ranked by the number of SUPERNUS PHARMACEUTICALS INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 55,989,248 shares outstanding at the time of that meeting.

Top SUPERNUS PHARMACEUTICALS INC. shareholders by shares voted, 2024-2025
#	Asset manager	% of shares outstanding
1	BlackRock	13.03%
2	Vanguard	12.88%
3	State Street	5.14%
4	MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST	4.48%
5	American Century	3.95%
6	Delaware/Macquarie	3.74%
7	Loomis Sayles	3.43%
8	Stephens Investment Management Group LLC	2.65%
9	Charles Schwab	2.61%
10	Fidelity	2.53%

Reported SUPERNUS PHARMACEUTICALS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

SUPERNUS PHARMACEUTICALS INC. beneficial owners on record for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
BlackRock	17.30%	13F
BlackRock, Inc. and its affiliates	14.64%	DEF14A
Vanguard Group	11.01%	13F
Armistice Capital, LLC	8.64%	DEF14A
Jack A. Khattar +	7.20%	DEF14A
Millennium Management LLC	5.86%	13G
Vanguard Portfolio Management	5.83%	13G
Dimensional Fund Advisors	5.19%	13F
Macquarie Group Limited and its affiliates	4.70%	DEF14A
State Street	3.83%	13F

Percentages above are of 55,989,248 shares outstanding, as reported by SUPERNUS PHARMACEUTICALS INC. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from SUPERNUS PHARMACEUTICALS INC.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At SUPERNUS PHARMACEUTICALS INC.'s shareholder meeting held 2025-06-16, in the 2024-2025 proxy season, 329 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,745 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — to approve, on a non-binding basis, the compensation paid to our named executive officers; — FOR was 96% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: SUPERNUS PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-06-17.

SUPERNUS PHARMACEUTICALS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.